Bio-Rad Laboratories, Inc. (NYSE: BIO)

Bio-Rad Laboratories, Inc. (NYSE: BIO) manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. 

The company focuses on providing other companies in the biotechnology space with the technology, documentation, and equipment needed to develop new therapeutics and vaccines. 

This puts the company in the perfect position. 

For some time now, the U.S. has been going through an evolution in medicine. New technologies have given experts an understanding of how the human body ticks like never before, paving the way for the development of cures for some of the world’s most devastating conditions. 

Just 30 years ago, hepatitis C was a death sentence. Today, it can be cured. The same goes for a wide array of ailments for which advancements in medicine have led to cures or better treatments. 

For all of this to happen, clinical trials must take place and equipment and data must be acquired. As such, companies like Bio-Rad Laboratories realize high levels of demand.

As of the third quarter of 2021, revenue came in at $715.2 million representing year-over-year growth of more than 10%. As the medical community works to solve more significant problems, the company’s leading products and services will continue to experience high levels of demand.